AndrewJPiperMD

PubMed

• A Real-World Study of Patient Characteristics and Clinical Outcomes inMutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into ...
  Emmeline Academia, Susumu S Kobayashi, Hollis Viray, Andrew J Piper-Vallillo, Page Widick, Meghan Shea, Deepa Rangachari, Paul A VanderLaan, Daniel B Costa> ;Cancers. 2024 Mar 7
• 6 citations
  Osimertinib in NSCLC With Atypical-Activating Mutations: A Retrospective Multicenter Study.
  Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, Laura Huppert, Julia K Rotow, Hatim Husain, Susan Stewart, Rosemary Cobb, Heather A Wakelee, Collin M Blakely, M...> ;JTO Clinical and Research Reports. 2023 Mar 1
• 3 citations
  Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
  Daniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, Page Widick, Deepa Rangachari, Jennifer L Wilson, Sidharta P Gangadharan, Joseph A Aronovitz, Stuart M Ber...> ;Lung Cancer. 2022 Oct 1
• 12 citations
  Chemotherapy plus immunotherapy versus chemotherapy plus bevacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib
  Maya N. White, Andrew J. Piper-Vallillo, Rebecca M. Gardner, Kristen M. Cunanan, Joel W. Neal, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Thomas T. Chen, Leci...> ;Clinical Lung Cancer. 2021 Nov 11
• 3 citations
  Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.
  Isaac A. Klein, Shoshana M. Rosenberg, Kerry L. Reynolds, Leyre Zubiri, Rachel P. Rosovsky, Andrew J. Piper-Vallillo, Xin Gao, Genevieve M. Boland, Aditya Bardia, Rach...> ;The Oncologist. 2021 Aug 1
• Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations.
  Andrew J. Piper-Vallillo, Susumu Kobayashi, Daniel B. Costa> ;JTO Clinical and Research Reports. 2021 Mar 1
• 5 citations
  Time to SARS-CoV-2 clearance among patients with cancer and COVID-19.
  Wenxin Xu, Andrew J. Piper-Vallillo, Poorva Bindal, Jonathan W. Wischhusen, Jaymin M. Patel, Daniel B. Costa, Mary Linton B. Peters> ;Cancer Medicine. 2021 Feb 9
• 6 citations
  Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
  Andrew J. Piper-Vallillo, Meghan J. Mooradian, Catherine B. Meador, Beow Y. Yeap, Jennifer L Peterson, Mustafa Sakhi, Andrew Do, Leyre Zubiri, Sara Stevens, Jeanne Gri...> ;JTO Clinical and Research Reports. 2021 Jan 1
• 11 citations
  Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer.
  Andrew J. Piper-Vallillo, Brian Halbert, Deepa Rangachari, Susumu Kobayashi, Daniel B. Costa> ;JTO Clinical and Research Reports. 2020 Jun 20
• 93 citations
  Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
  Andrew J. Piper-Vallillo, Lecia V. Sequist, Zofia Piotrowska> ;Journal of Clinical Oncology. 2020 Jun 18
• 22 citations
  Cases of ROS1 -rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
  Kartik Sehgal, Andrew J. Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B. Costa> ;Precision Cancer Medicine. 2020 Jun 15
• 15 citations
  Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib.
  Andrew J. Piper-Vallillo, Daniel B. Costa, Marwa A. Sabe, Aarti Asnani> ;JACC. Cardiooncology. 2020 Mar 1
• 1 citations
  Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib.
  Andrew J. Piper-Vallillo, Lecia V. Sequist> ;JACC. Cardiooncology. 2019 Dec 1
• 4 citations
  Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
  Andrew J. Piper, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari> ;Translational Lung Cancer Research. 2019 Oct 1
• 19 citations
  Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC).
  Andrew J. Piper, Jennifer L. Clark, Jose Mercado-Matos, Asia N. Matthew-Onabanjo, Chung-Cheng Hsieh, Ali Akalin, Leslie M. Shaw> ;Plos One. 2019 Aug 8
• 14 citations
  Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disr...
  Jose Mercado-Matos, Jennifer L. Clark, Andrew J. Piper, Jenny Janusis, Leslie M. Shaw> ;The Journal of Biological Chemistry. 2017 May 12
• Join now to see all